Home
About
Who We Are
Mission
Values
Science & Pipeline
Patients
Leadership
Investors & Media
Overview
Press Releases
Events
Publications / Presentations
Financial Information
Corporate Governance
Stock Information
Investor Resources
Careers
Contact Us
LinkedIn
Privacy
Terms of Use
Phase 3 Placeholder
by
Kinnate Biopharma
|
Sep 12, 2020
Phase 2 Placeholder
by
Kinnate Biopharma
|
Sep 12, 2020
Phase 1 Placeholder
by
Kinnate Biopharma
|
Sep 12, 2020
Undisclosed Targets
by
Kinnate Biopharma
|
Sep 12, 2020
Search for:
Recent Posts
Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board
Kinnate Biopharma Closes $98 Million Series C Financing
Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer
Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year
Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer
Recent Comments
Archives
September 2020
August 2020
July 2020
June 2020
May 2020
December 2019
April 2018
Categories
Article
News
Meta
Log in
Entries feed
Comments feed
WordPress.org
On April 3, 2024, XOMA completed its acquisition of Kinnate.
Visit XOMA.com
CLOSE
Recent Comments